Aquestive Therapeutics, Inc. Common Stock
AQSTAquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing medicines to address unmet medical needs. The company specializes in developing proprietary formulations of drugs for respiratory, epilepsy, and other disorders, utilizing its core patent-protected oral and transdermal technologies.
Company News
Rosen Law Firm reminds investors in Aquestive Therapeutics (AQST) who purchased securities between June 16, 2025 and January 8, 2026 of the May 4, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aquestive made false or misleading statements regarding its New Drug Application for Anaphylm, specifically concealing ...
A class action lawsuit has been filed against Atara Biotherapeutics alleging securities fraud. The complaint claims the company made false statements about manufacturing issues and deficiencies in the ALLELE study that would likely prevent FDA approval of tabelecleucel. Investors who purchased Atara securities between May 20, 2024 and January 9, ...
A class action lawsuit has been filed against Aquestive Therapeutics for allegedly misleading investors about FDA approval prospects for its Anaphylm drug. The company failed to disclose FDA-identified deficiencies that precluded approval by the January 31, 2026 PDUFA date. Following the January 9, 2026 announcement of these deficiencies, Aquesti...
The Portnoy Law Firm has announced a class action lawsuit against Aquestive Therapeutics on behalf of investors who purchased securities between June 16, 2025 and January 8, 2026. The lawsuit alleges that Aquestive made false statements about its Anaphylm drug approval prospects and failed to disclose FDA-identified deficiencies in the NDA applic...
A class action lawsuit has been filed against Aquestive Therapeutics and its officers for alleged securities fraud. The complaint alleges that defendants made materially false statements about the timeline for FDA approval of their Anaphylm drug and concealed significant human factors risks related to the sublingual film product that could impact...
